THERAPY DOSSIER · th-c9b15300ee99

Nerve growth factor gene plasmid (pCMV6-NGF) in PLGA nanobubbles released by ultrasound-mediated destruction

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28280337 ↗2017Reported benefit

Nerve growth factor delivery by ultrasound-mediated nanobubble destruction as a treatment for acute spinal cord injury in rats.

RatSpinal cord injuryContusionSprague-Dawleymaleintravenous via tail vein, with ultrasound applied over the injury siteFormulation only: plasmid 1 mg/mL added to 2 mL chloroform…immediately after acute spinal cord injury

Model: Modified Allen weight-drop contusion at the tenth thoracic segment, 10 g rod dropped from 5 cm and left resting for 3 minutes after laminectomy

NGF/PLGA nanobubbles with ultrasound gave the highest NGF mRNA and protein expression (P < 0.05), preserved Nissl bodies (P < 0.01), reduced TUNEL-positive cells (P < 0.01) and higher BBB scores from day 7 onward compared with all three control groups.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…